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Poster Session II S339(95% CI 16 – 44%) by one year. The cumulative incidence of pri-
mary disease relapse was 23% (95% CI 13 – 41%) at 1 year. CMV
reactivation differed according to recipient and donor CMV
serostatus. EBV reactivation occurred in 54% (95% CI 40% -
71%). Preemptive rituximab therapy controlled EBV in the majority
of cases; however, PTLD was diagnosed in 5 cases, and was fatal in
one. A regimen of ATG 7.5mg/kg today ending on day -1 effectively
prevents grade III-IV acute GVHD and severe chronic GVHD in
6-7/8 mismatched unrelated donor HCT.519
INFLUENCE OF GENOMIC STRUCTURAL VARIANTS ON GVHD AND RE-
LAPSE RISK IN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC
HSCT
Larson, G.P.1, Palmer, J.2, Qian, D.2, Forman, S.3, Senitzer, D.4,
Nakamura, R.3 1Beckman Research Institute of the City of Hope, Duarte,
CA; 2Division of Biostatistics; 3Hematology; 4Histocompatibility Laboratory
Copy number variants (CNV) contribute to the risk of multiple
common diseases and are implicated in unfavorable clinical out-
comes in HSCT. The role of CNVs bearing immuno-tolerance
genes (mHAg) has been demonstrated for UGT2B17 in HLA-
matched siblings after HSCT (McCarroll, et alNat Genet 2009). Ho-
mozygous CNV deletion trans€ıplant donors mismatched with
CNV+ recipients may harbor immune systems na€ıve to proteins
present within the recipient eliciting GVHD demonstrating a grow-
ing role for CNVs in transplant medicine. Allogeneic HSCT, a po-
tentially curative therapy for recurrent non-Hodgkin lymphoma
(NHL), is often compromised by transplant-mediated GVHD
thereby jeopardizing patient survival. Owing to known differences
in CNV allele frequencies in ethnically diverse populations com-
bined with the racially diverse composition of NHL patients seen
at our institution, the incidence of CNV-mediated GVHD may
very widely. To test this premise, we are examining the affect of pop-
ulation-specific CNVs on GVHD in a cohort of NHL patients.
We are investigating GVHD in 292 patients who underwent
HSCT to 1) determine the genetic admixture of our patients, 2) sub-
sequently use genetic ancestry to guide the selection of CNVs for
GVHD association testing, and 3) develop a novel mass spectrome-
try based platform to genotype CNVs. In our initial group of 85 pa-
tients who underwent allo-HSCT (64 related and 21 unrelated
donors), grade II-IV acute GVHD occurred in 43 patients, and 21
experienced NHL relapse. Forty-eight patients self-reported as
non-Hispanic Caucasian, 3 African American, 5 Asian, and 29 His-
panic or Latino. Genetic admixture estimates with a panel of 100
Ancestry Informative Markers were used to define genetic ancestry
and correlate to self-reported ethnicity. Admixture analysis on self-
reported Hispanics showed that 69% (20/29) contained. 10% Am-
erIndian ancestry. Weighted ancestry estimates in 3 HapMap popu-
lations based on genetic proportions observed in our patients
indicate numerous CNV alleles as potential targets, 48 of these
have allele frequencies . 10% in our cohort and represent possible
targets for donor-recipient mismatches.
We are genotyping donor/recipient pairs for a select group of
CNVs in conjunction with UGT2B17 using mass spectroscopy to
correlate CNV discordant pairs with GVHD. Approaches like this
are applicable to the racially diverse patient populations commonly
seen at institutions performing HSCT and may improve clinical
outcomes.520
A PHASE I/II STUDY OF CHEMOTHERAPY FOLLOWED BY DONOR LYM-
PHOCYTE INFUSION PLUS INTERLEUKIN-2 FOR RELAPSED ACUTE LEU-
KEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Inamoto, Y., Fefer, A., Sandmaier, B.M., Gooley, T.A., Warren, E.H.,
Petersdorf, S.H., Sanders, J.E., Storb, R.F., Appelbaum, F.R.,
Martin, P.J., Flowers, M.E.D. Fred Hutchinson Cancer Research Center,
Seattle, WA
Introduction: Efficacy of donor lymphocyte infusion (DLI) for
relapsed acute leukemia after allogeneic hematopoietic cell trans-
plantation (HCT) is limited. We hypothesized that interleukin-2
(IL-2) combined with DLI after chemotherapy might augmentgraft-versus-leukemia effects. To identify a safe and effective IL-2
regimen, a phase I/II study of DLI plus IL-2 therapy was performed.
Methods: Patients with relapsed acute myeloid leukemia (AML) or
acute lymphoblastic leukemia (ALL) after allogeneic HCT were el-
igible for this study. After chemotherapy, patients received DLI
(1x108 CD3/kg for patients with related donors, and 0.1x108 CD3/
kg for those with unrelated donors) and an escalating dose of induc-
tion IL-2 (Aldesleukin, Chiron, CA; 1.0, 2.0, or 3.0x106 IU/m2/day
representing levels I, Ia and II) for 5 days followed by maintenance
(1.0x106 IU/m2/day) for 10 days as a continuous intravenous infu-
sion. Study toxicities were prespecified. An excess study toxicity
rate was defined as any incidence where the lower limit of the 80%
one-sided confidence interval exceeded 25%. To examine the poten-
tial efficacy of this therapy, disease-free survival (DFS) was estimated
according to diagnosis and remission status at time of DLI.
Results:Atotalof17patients(11withAMLand6withALL)withmedian
age33years(range19-61)wereenrolledinthisstudy.Donorswererelated
siblingsfor13patientsandunrelatedvolunteersfor4patients.Sixteenpa-
tientshadapriorhistoryofGVHD.ThemediantimefromHCTtoche-
motherapy was 11.8 months (range 3-121). The median time from
chemotherapytoDLIwas61days(range36-91).Outcomesaresumma-
rizedintheTable.IL-2relatedtoxicitieswerereversibleinallexceptin1
patientatlevelIIwhodiedofcapillaryleaksyndrome.GradesIII-IVacute
GVHDdevelopedin5patients,andextensivechronicGVHDdeveloped
in8.Studytoxicitiesdevelopedin1patientatIL-2doselevelI,2patientsat
levelIaand1patientat levelII.Eightpatientshadacompleteremission
afterchemotherapypriortoDLI,and2additionalpatientshadacomplete
remissionafterDLIplusIL-2therapy.DFSat1yearwas40%forpatients
withAMLincomplete remissionatDLI (n55) and8%for thosewith
AMLnotinremission(n56)orALLinanystageatDLI(n56).
Conclusion: The maximal tolerated induction dose of IL-2 com-
bined with DLI appears to be 1.0x106 IU/m2/day. IL-2 administra-
tion after DLI might increase the incidence of chronic GVHD.
Table 1. GVHD, study toxicity and remission duration after
DLI according to IL-2 dose level
RemissionPatient# DiagnosisIL-2 Dose
LevelAcute
GVHDChronic
GVHDStudy
Toxicity*Duration after
DLI (Month)1 AML I 0 NA N 02 AML I III Extensive N 333 AML I III Extensive N 354 AML I 0 Extensive N 05 ALL I 0 0 N 06 ALL I III Extensive Y (GVHD) 87 ALL I 0 0 N 58 AML Ia 0 NA N 09 AML Ia 0 0 N 010 AML Ia II Extensive N 911 AML Ia 0 Extensive N 512 AML Ia IV Extensive Y (GVHD) 4713 AML Ia 0 0 N 614 AML Ia 0 0 N 315 ALL Ia 0 Limited N 016 ALL Ia III Extensive Y (IL-2) 1217 ALL II 0 NA Y (IL-2) 0*Death related to acute or chronic GVHD, development of acute or
chronic GVHD with inability to decrease the dose of prednisone to
less than 1mg/kg/day within 1 month after initiating treatment for
GVHD, or life threatening or fatal organ toxicity attributable to IL-2.521
INTERFERON-GAMMA PRODUCTION BY ALLOGENEIC FOXP3+ REGULA-
TORY T CELLS PROMOTES SURVIVAL IN EXPERIMENTAL GVHD
Koenecke, C.1,2, Lee, C.-W.1,2, F€ohse, L.2, Ganser, A.1, F€orster, R.2,
Prinz, I.2 1Hannover Medical School, Hannover, Germany; 2Hannover
Medical School, Hannover, Germany
Background and Aims:Adoptive transfer of natural FoxP3+ regula-
tory T cells (Tregs) has been shown to prevent lethal GvHD. It is
emerging that Tregs are a stable lineage that do not revert into harm-
ful FoxP3 effector cells. However, we have recently found that Tregs
S340 Poster Session IIproduce large amounts of interferon-gamma (IFN-g) under inflam-
matory conditions. Here we address the role of IFN-g production by
Tregs in the course of experimental GvHD.
Methods: In a C57BL/6 into BALB/c mouse model of acute GvHD
we monitored the intracellular cytokine expression of Tregs using
FoxP3-reporter mice (C56BL/6) and congenic markers. We ad-
dressed the role of IFN-g in experimental GvHD i) by employing
the IFN-g blocking mAb XMG1.2 and ii) by adoptive transfer of
Tregs and/ or effector T cells purified from ifng–/– mice. GvHD
severity was monitored by survival, clinical score and histological
analysis.
Results: Co-transferred Tregs in a C57BL/6 into BALB/c model
readily secreted IFN-g but stably remained FoxP3+ and prevented
lethal GvHD. Intracellular staining revealed that at day 4 after trans-
plantation approximately 35% of these allogeneic Tregs produced
IFN-g. In this experimental setting blocking of IFN-g with mAb
completely abolished the protective effect of Tregs and led to early
death from exacerbated GvHD. Of note, we also observed a similar
fatal outcome of experimental GvHD when we co-transferred
ifng–/– Tregs and wild type effector T cells.
Conclusions: Our data suggest that IFN-g should not be regarded
as an adverse pro-inflammatory cytokine under the highly inflamma-
tory environment of acute GvHD since it is required for the protec-
tive action of Tregs. We hypothesize that this may be due to
a deviation of effector T cell profiles towards Th17. In ongoing
experiments we therefore address this issue by employing effector
T cells from il17a–/– / il17f–/– double knock-out mice.522
DONOR-LYMPHOCYTE INFUSION IN PATIENTS WITH PERSISTENT OR
RECURRENTMULTIPLEMYELOMA AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Beitinjaneh, A.1, Shah, N.1, Bashir, Q.1, Parmar, S.1, Hosing, C.1,
Popat, U.1, Anderlini, P.1, Dinh, Y.1, Qureshi, S.1, Rondon, G.1,
Champlin, R.E.1, Giralt, S.A.2, Qazilbash, M.H.1 1University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2Memorial Sloan Kettering
Cancer Center, New York, NY
Objective: The graft-versus-leukemia (GVL) effect of donor-lym-
phocyte infusions (DLI) is well documented in hematologic malig-
nancies, including multiple myeloma (MM). We evaluated the role
of DLI in persistent or recurrent MM after allogeneic hematopoietic
stem cell transplantation (allo HCT).
Materials and Methods: We identified 23 patients with MM, who
received DLI at UT-MD Anderson Cancer Center between 7/1996
-6/2008. Patients had persistent or recurrent disease after allo HCT,
and were treated with DLI collected from their original allo HCT
donors.
Results: Nineteen patients received DLI from matched related do-
nors (MRD) and 4 from matched unrelated donors (MUD). Median
age at DLI was 51 years (range: 38-62). A total of 33 DLI doses were
administered. Seventeen patients received 1 infusion, 4 patients re-
ceived 2, and 2 patient received 4 infusions. Median interval between
allo HCT and the first DLI was 8.2 months (range: 2.9 to 119.5).
Median follow up from the first DLI was 18 months (range 1-126).
Twenty-six DLI (78%) were given without preceding cytoreductive
chemotherapy. The median DLI dose was 3.5 x 107 CD3+ T cells
(range 0.5 to 14.8 x 107). Overall response rate was 30%, with 10
of 33 DLI doses associated with objective clinical responses (3 CR,
5 VGPR, 2 PR). Thirteen (39%) additional DLI were followed by
stable disease. Median response duration was 5 months (range 2-
10). ORR to DLI in relapsed disease was 10% (2/20), compared to
61% (8/13) for residual disease (p 5 0.0048). Grade II-IV acute
graft-versus-host disease (GVHD) was seen in 6 (26%) patients,
with median onset of 5 weeks fromDLI. None of the patients devel-
oped chronic GVHD after DLI. Median overall survival from the
first DLI was 18.6 months.
Conclusions: DLI is associated with objective clinical responses
patients with relapsed or persistent MM, with a significantly higher
response rate in patients with persistent vs. relapsed disease. The risk
of acute GVHD was low. The role of DLI needs to be furtherexplored in prospective clinical trials for patients with relapsed or
persistent MM.523
KINETICS OF MURINE GVHD INDUCTION ACROSS MINOR AND MAJOR
HISTOCOMPATIBILITY BARRIERS
Vasey, A.E., Baker, J.B., Leveson-Gower, D.B., Negrin, R.S. Stanford
University, Stanford, CA
It is known that Graft-vs-Host Disease (GVHD) occurs in
response to minor histocompatibility antigens, but little is known
about the kinetics of donor T cell proliferation and homing in minor
mismatch models of allogeneic hematopoietic cell transplantation
(HCT). This is in contrast tomodels across major histocompatibility
barriers, where early development of GVHDhas been better charac-
terized. Yet, because minor mismatch models are more similar to
clinical HCT, it is critical to understand how GVHD develops
across minor barriers. To investigate temporal and spatial events
of donor T cell activation and homing, side-by-side transplants
were conducted using bone marrow and enriched CD4 and CD8
T cells (Tcon) from donor C56BL/6 mice (H2b) into either major
mismatched Balb/c (H2d), or minor mismatched Balb.b (H2b), irra-
diated recipients. Balb/c mice received 1x106 Tcon while Balb.b
mice received 15x106 Tcon, based on titration experiments. Prolifer-
ation and migration of donor Tcon was monitored using in vivo and
ex vivo bioluminescent imaging, and CFSE labeling. Expression of
T cell activation and homing markers was examined using flow cy-
tometry analysis of donor CD4 andCD8 cells re-isolated from trans-
planted mice. Donor Tcon from Balb.b mice exhibited significantly
reduced proliferation at both 3 and 6 days post transplant (p\0.01, n
5 43). But, mirroring our earlier findings inmajormismatchmodels,
donor Tcon in the minor model homed to nodal sites by day 3, fol-
lowed by an exit to tissues by day 6, albeit reduced. No significant
differences in the expression of the activation and homing markers
examined were noted by day 3, although there was variation across
tissues and between CD4 and CD8 cells. By day 6, donor T cells
re-isolated from Balb.b recipients had reduced levels of a4b7 and
P-selectin, and increased retention of CD62L. These data support
the idea that early events of donor T cell activation, particularly spa-
tially, are similar across minor and major histocompatiblity barriers,
reinforcing the usefulness of both models as translational research
tools. More importantly, these data suggest that delays in visible
GVHD onset in minor mismatch tranpslants arise from temporal
differences in the effector phase of T cell action, rather than delays
in the initiation phase. These findings support targeting very early
events in T cell activation as the most effective method of reducing
GVHD in clinical settings.524
ROLE OF CLINICAL LABORATORY MARKERS OF INFLAMMATION IN AS-
SESSING CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) ACTIVITY
AND SEVERITY
Grkovic, L.1, Baird, K.2, Steinberg, S.M.3, Pulanic, D.4, Cowen, E.W.5,
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5NIH/NCI, Bethesda, MD; 6NIH/NCI, Bethesda, MD; 7Hackensack
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Background: cGVHD is a major cause of health problems and mor-
tality after allogeneic HCT. Routine clinical laboratory parameters
are established in outcomes monitoring of systemic inflammatory
or autoimmune disease, but their value in cGVHD is unknown.
To determine the relationship between laboratory markers of
